Cemiplimab is only the second anti–PD-1/PD-L1 agent to show efficacy in advanced NSCLC as both monotherapy and in combination with chemotherapy for both squamous and non-squamous histologies6,12. The gene discussed is CD274; the disease is non-small cell lung carcinoma.